New hope for tough eczema: abrocitinib studied in patients failed by biologics
NCT ID NCT06899204
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study looks at how well the drug abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried and not responded to, or couldn't tolerate, up to two other biologic treatments. Researchers will track 150 participants across the U.S. to measure improvements in skin symptoms and itching over 16 weeks. The goal is to understand real-world effectiveness for this hard-to-treat group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGNew York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.